NO984124D0 - Fremgangsmåte for å hemme adenylsuksinatsyntetaseaktivitet i metyltioadenosinfosforylasemanglende celler - Google Patents
Fremgangsmåte for å hemme adenylsuksinatsyntetaseaktivitet i metyltioadenosinfosforylasemanglende cellerInfo
- Publication number
- NO984124D0 NO984124D0 NO984124A NO984124A NO984124D0 NO 984124 D0 NO984124 D0 NO 984124D0 NO 984124 A NO984124 A NO 984124A NO 984124 A NO984124 A NO 984124A NO 984124 D0 NO984124 D0 NO 984124D0
- Authority
- NO
- Norway
- Prior art keywords
- mtase
- activity
- loss
- methylthioadenosine
- cells
- Prior art date
Links
- 108010034457 5'-methylthioadenosine phosphorylase Proteins 0.000 title abstract 7
- 102100034187 S-methyl-5'-thioadenosine phosphorylase Human genes 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 6
- 230000000694 effects Effects 0.000 title abstract 4
- 102000003960 Ligases Human genes 0.000 title abstract 2
- 108090000364 Ligases Proteins 0.000 title abstract 2
- 230000002950 deficient Effects 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 abstract 5
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 abstract 5
- 229950006790 adenosine phosphate Drugs 0.000 abstract 5
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000000779 depleting effect Effects 0.000 abstract 2
- ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 abstract 1
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 abstract 1
- 229930024421 Adenine Natural products 0.000 abstract 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 abstract 1
- MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000009396 hybridization Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/963—Methods of stopping an enzyme reaction or stabilizing the test materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/612,542 US5840505A (en) | 1993-12-29 | 1996-03-08 | Method for inhibiting adenylosuccinate synthetase activity in methylthioadenosine phosphorylase deficient cells |
| PCT/US1997/001193 WO1997032994A1 (en) | 1996-03-08 | 1997-01-27 | Method for inhibiting adenylosuccinate synthetase activity methylthioadenosine phosphorylase deficient cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO984124L NO984124L (no) | 1998-09-07 |
| NO984124D0 true NO984124D0 (no) | 1998-09-07 |
Family
ID=24453611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO984124A NO984124D0 (no) | 1996-03-08 | 1998-09-07 | Fremgangsmåte for å hemme adenylsuksinatsyntetaseaktivitet i metyltioadenosinfosforylasemanglende celler |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5840505A (no) |
| EP (1) | EP0902839B1 (no) |
| JP (1) | JP2000509247A (no) |
| KR (1) | KR19990087627A (no) |
| CN (1) | CN1213406A (no) |
| AT (1) | ATE357223T1 (no) |
| AU (1) | AU722813B2 (no) |
| BR (1) | BR9708002A (no) |
| CA (1) | CA2244733A1 (no) |
| CZ (1) | CZ286698A3 (no) |
| DE (1) | DE69737499D1 (no) |
| EA (1) | EA001988B1 (no) |
| HU (1) | HUP9901858A3 (no) |
| IL (1) | IL126114A0 (no) |
| NO (1) | NO984124D0 (no) |
| NZ (1) | NZ331088A (no) |
| PL (1) | PL328810A1 (no) |
| RO (1) | RO118210B1 (no) |
| UA (1) | UA47465C2 (no) |
| WO (1) | WO1997032994A1 (no) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6210917B1 (en) * | 1993-12-29 | 2001-04-03 | The Regents Of The University Of California | Method for suppressing multiple drug resistance in cancer cells |
| US6214571B1 (en) * | 1993-12-29 | 2001-04-10 | The Regents Of The University Of California | Method for inhibiting adenylosuccinate synthetase activity in malignant methylthioadenosine phosphorylase deficient cells |
| US6911309B2 (en) * | 1993-12-29 | 2005-06-28 | The Regents Of The University Of Californnia | Nucleic acids encoding MTAse |
| AU2001297765A1 (en) * | 2000-12-05 | 2002-10-21 | Incyte Genomics, Inc. | Ligases |
| US20040043959A1 (en) * | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| US20040127435A1 (en) * | 2002-08-02 | 2004-07-01 | Regents Of The University Of California | Uses for inhibitors of inosine monophosphate dehydrogenase |
| EP1594900A2 (en) * | 2003-02-14 | 2005-11-16 | Salmedix, Inc. | Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers |
| US20060041013A1 (en) * | 2004-08-18 | 2006-02-23 | Brittain Jason E | Alanosine formulations and methods of use |
| WO2009014642A1 (en) * | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer |
| CA3045752A1 (en) * | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
| JP7016958B2 (ja) * | 2017-12-21 | 2022-02-07 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | アデノシンおよび／またはメチルチオアデノシンの酵素媒介枯渇方法 |
| CN110124038A (zh) * | 2019-05-08 | 2019-08-16 | 山东大学齐鲁医院 | 腺苷酸琥珀酸合成酶基因和/或其编码的蛋白的新应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4792520A (en) * | 1984-02-16 | 1988-12-20 | University Of Cincinnati | Methods and kits for identifying mutagenic agents and molecular mutations in DNA in mammalian cells |
| US4822736A (en) * | 1984-07-05 | 1989-04-18 | Baylor College Of Medicine | Amplification of adenosine deaminase genes in mammalian cells using adenosine, alanosine, uridine, and deoxycoformycin |
| US5030623A (en) * | 1986-03-27 | 1991-07-09 | The Regents Of The University Of California | Methods for increasing extracellular adenosine and for stabilizing mast cells |
| US5118601A (en) * | 1986-03-27 | 1992-06-02 | The Regents Of The University Of California | Method of screening purine nucleoside compounds or analogs for the ability to enhance the cellular synthesis and release of adenosine |
| PL181667B1 (pl) * | 1993-12-29 | 2001-08-31 | Univ California | Sposób wykrywania obecnosci katalitycznie aktywneji katalitycznie nieaktywnej fosforylazy metylotioadenozynowej (MTAzy), wyizolowany polinukleotyd oraz zrekombinowany wektor ekspresyjny PL |
-
1996
- 1996-03-08 US US08/612,542 patent/US5840505A/en not_active Expired - Fee Related
-
1997
- 1997-01-27 EA EA199800806A patent/EA001988B1/ru not_active IP Right Cessation
- 1997-01-27 CZ CZ982866A patent/CZ286698A3/cs unknown
- 1997-01-27 UA UA98105274A patent/UA47465C2/uk unknown
- 1997-01-27 CA CA002244733A patent/CA2244733A1/en not_active Abandoned
- 1997-01-27 IL IL12611497A patent/IL126114A0/xx unknown
- 1997-01-27 RO RO98-01362A patent/RO118210B1/ro unknown
- 1997-01-27 EP EP97903962A patent/EP0902839B1/en not_active Expired - Lifetime
- 1997-01-27 CN CN97192895A patent/CN1213406A/zh active Pending
- 1997-01-27 HU HU9901858A patent/HUP9901858A3/hu unknown
- 1997-01-27 KR KR1019980707079A patent/KR19990087627A/ko not_active Application Discontinuation
- 1997-01-27 AT AT97903962T patent/ATE357223T1/de not_active IP Right Cessation
- 1997-01-27 PL PL97328810A patent/PL328810A1/xx unknown
- 1997-01-27 DE DE69737499T patent/DE69737499D1/de not_active Expired - Lifetime
- 1997-01-27 JP JP9531750A patent/JP2000509247A/ja not_active Ceased
- 1997-01-27 WO PCT/US1997/001193 patent/WO1997032994A1/en active IP Right Grant
- 1997-01-27 NZ NZ331088A patent/NZ331088A/xx unknown
- 1997-01-27 AU AU18388/97A patent/AU722813B2/en not_active Ceased
- 1997-01-27 BR BR9708002A patent/BR9708002A/pt not_active Application Discontinuation
-
1998
- 1998-09-07 NO NO984124A patent/NO984124D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RO118210B1 (ro) | 2003-03-28 |
| EA001988B1 (ru) | 2001-10-22 |
| NO984124L (no) | 1998-09-07 |
| EA199800806A1 (ru) | 1999-02-25 |
| IL126114A0 (en) | 1999-05-09 |
| CA2244733A1 (en) | 1997-09-12 |
| HUP9901858A3 (en) | 1999-12-28 |
| KR19990087627A (ko) | 1999-12-27 |
| EP0902839A1 (en) | 1999-03-24 |
| EP0902839A4 (en) | 2004-06-30 |
| DE69737499D1 (de) | 2007-05-03 |
| JP2000509247A (ja) | 2000-07-25 |
| HUP9901858A2 (hu) | 1999-09-28 |
| BR9708002A (pt) | 1999-07-27 |
| UA47465C2 (uk) | 2002-07-15 |
| CZ286698A3 (cs) | 1999-03-17 |
| AU1838897A (en) | 1997-09-22 |
| NZ331088A (en) | 2000-08-25 |
| PL328810A1 (en) | 1999-02-15 |
| CN1213406A (zh) | 1999-04-07 |
| US5840505A (en) | 1998-11-24 |
| AU722813B2 (en) | 2000-08-10 |
| ATE357223T1 (de) | 2007-04-15 |
| EP0902839B1 (en) | 2007-03-21 |
| WO1997032994A1 (en) | 1997-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Canman et al. | Induction of resistance to fluorodeoxyuridine cytotoxicity and DNA damage in human tumor cells by expression of Escherichia coli deoxyuridinetriphosphatase | |
| Kono et al. | Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors | |
| Birnie et al. | Studies of fluorinated pyrimidines. XVIII. The degradation of 5-fluoro-2'-deoxyuridine and related compounds by nucleoside phosphorylase | |
| Major et al. | 5-Fluorouracil incorporation in DNA of human breast carcinoma cells | |
| NO984124D0 (no) | Fremgangsmåte for å hemme adenylsuksinatsyntetaseaktivitet i metyltioadenosinfosforylasemanglende celler | |
| Hershfield et al. | Resistance of an adenosine kinase-deficient human lymphoblastoid cell line to effects of deoxyadenosine on growth, S-adenosylhomocysteine hydrolase inactivation, and dATP accumulation. | |
| Gallo et al. | The Enzymatic Mechanisms for Deoxythymidine Synthesis in Human Leukocytes: I. SUBSTRATE INHIBITION BY THYMINE AND ACTIVATION BY PHOSPHATE OR ARSENATE | |
| Cao et al. | Uridine phosphorylase (−/−) murine embryonic stem cells clarify the key role of this enzyme in the regulation of the pyrimidine salvage pathway and in the activation of fluoropyrimidines | |
| AU4180996A (en) | Suicide genes and combinations of pyrimidine nucleoside and nucleobase analogues with suicide genes for gene therapy | |
| Brink et al. | 9-β-D-Arabinofuranosyladenine as an inhibitor of metabolism in normal and neoplastic cells | |
| Dusseau et al. | Analysis of uracil DNA glycosylase in human colorectal cancer | |
| Tabata et al. | Antitumor mechanisms of 3′-ethynyluridine and 3′-ethynylcytidine as RNA synthesis inhibitors: development and characterization of 3′-ethynyluridine-resistant cells | |
| Ghoda et al. | Substrate specificities of 5′-deoxy-5′-methylthioadenosine phosphorylase from Trypanosoma brucei brucei and mammalian cells | |
| Senesi et al. | A specific adenosine phosphorylase, distinct from purine nucleoside phosphorylase | |
| Plagemann et al. | Inhibition of de novo pyrimidine nucleotide and DNA synthesis and growth of cultured Novikoff rat hepatoma cells and other cell lines by pyrazofurin (NSC 143095) | |
| Schwartz et al. | 5-Ethoxy-2′-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression | |
| Lönn et al. | 5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole | |
| Zheng et al. | Novel nucleoside-based antimalarial compounds | |
| Caradonna et al. | DNA glycosylases | |
| Lönn et al. | Increased levels of DNA lesions induced by leucovorin-5-fluoropyrimidine in human colon adenocarcinoma | |
| Iigo et al. | Potentiation of the chemotherapeutic action of 5′-deoxy-5-fluorouridine in combination with guanosine and related compounds | |
| Bartolucci et al. | Effect of cytidine analogs on cell growth and differentiation on a human neuroblastoma line | |
| Glazer et al. | Effect of sangivamycin and xylosyladenine on the synthesis and methylation of polysomal ribonucleic acid in Ehrlich ascites cells in vitro | |
| AKAZAWA et al. | The cytotoxicity of 5-fluorouracil is due to its incorporation into RNA not its inhibition of thymidylate synthase as evidenced by the use of a mouse cell mutant deficient in thymidylate synthase | |
| Miller et al. | Transfer Ribonucleic Acid Nucleotidyltransferase from Escherichia coli: III. KINETIC ANALYSIS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |